French pharmaceutical company Servier announced a $2.5 billion deal to acquire Day One Biopharmaceuticals, the maker of Ojemda — the first targeted therapy approved for pediatric low-grade glioma, the most common form of childhood brain cancer. Servier is offering $21.50 per share in cash, representing a 68% premium over Day One's closing price.

Ojemda generated $155.4 million in sales during 2025, its first full year on the U.S. market. A Phase 3 trial is underway to expand its use as a first-line treatment, and a European regulatory decision is expected later in 2026. The deal also brings Day One's pipeline, including DAY301, an antibody-drug conjugate targeting PTK7 currently in Phase 1 testing.

Servier CEO David Lee said the company remains "very open to areas that are really novel, innovative." Day One CEO Jeremy Bender noted that Servier's global footprint will help Ojemda "reach many more patients." The transaction is expected to close in Q2 2026.